Ignite Creation Date:
2025-12-24 @ 2:13 PM
Ignite Modification Date:
2026-02-22 @ 6:44 PM
Study NCT ID:
NCT03350295
Status:
COMPLETED
Last Update Posted:
2019-12-12
First Post:
2017-11-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
Sponsor:
Bayer
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2018-06-14
Start Date Type:
ACTUAL
Primary Completion Date:
2018-09-18
Primary Completion Date Type:
ACTUAL
Completion Date:
2018-12-14
Completion Date Type:
ACTUAL
First Submit Date:
2017-11-09
First Submit QC Date:
None
Study First Post Date:
2017-11-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2019-12-11
Last Update Post Date:
2019-12-12
Last Update Post Date Type:
ACTUAL